Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
NCT05548283 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs medical intervention. Both doctors and CF patients are trying to understand the best way to treat pulmonary exacerbations. This study is trying to answer the following questions about treating a pulmonary exacerbation: * Do participants have the same improvement in lung function and symptoms if they are treated with one type of antibiotic (called beta-lactams or β-lactams) versus taking two different types of antibiotics (tobramycin and β-lactams)? * Is taking one type of antibiotic just as good as taking two types?
Conditions Studied
Interventions
- DRUG Beta-lactam antibiotic
- DRUG Aminoglycoside
Study Locations (20)
Florida
- University of Florida — Gainesville
- Joe DiMaggio Children's Hospital — Hollywood
- Nemours Children's Clinic — Jacksonville
- University of Miami — Miami
- All Children's Hospital — St. Petersburg
California
- University of California San Diego — La Jolla
- Long Beach Memorial Medical Center — Long Beach
- CHOC Children's Hospital — Orange
- University of California at Davis Medical Center — Sacramento
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago
- Northwestern University — Chicago
- OSF Saint Francis Medical Center — Peoria
Indiana
- Indiana University Medical Center — Indianapolis
- Riley Hospital for Children — Indianapolis
Alabama
- The Children's Hospital Alabama, University of Alabama at Birmingham — Birmingham
Arizona
- Tucson Cystic Fibrosis Center — Tucson
District of Columbia
- Children's National Medical Center — Washington D.C.
Georgia
- Emory University — Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 730 participants |
| Start Date | 2023-04-23 |
| Est. Completion | 2026-11-15 |
| Phase | Phase 4 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05548283
The ClinicalTrials.gov registry entry for NCT05548283 describes a study currently listed as recruiting. It is categorized as Phase 4, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 730 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chris Goss, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 2 interventions — of which Beta-lactam antibiotic is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05548283 reports 20 study locations spanning 10 distinct geographic areas — top geographies include Florida, California, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05548283 about?
NCT05548283 is a clinical study titled "Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study". The purpose of this study is to look at pulmonary exacerbations in people with cystic fibrosis (CF) that need to be treated with antibiotics given through a tube inserted into a vein (intravenous or IV). A pulmonary exacerbation is a worsening of respiratory symptoms in people with CF that needs med...
What is the current status of trial NCT05548283?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 730 participants. The study started on 2023-04-23. Estimated completion is 2026-11-15.
What conditions does trial NCT05548283 study?
This clinical trial studies the following conditions: Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05548283?
The interventions under investigation include: Beta-lactam antibiotic (DRUG), Aminoglycoside (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05548283?
This trial is sponsored by Chris Goss, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05548283 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.